Opportunities to enhance protections for individualized interventions involving gene-editing Authors: Jeremy Sugarman Published: 2026 Main text The revelation of the previously unreported tragic death of a 6-year-old girl in Shanghai who received an experimental gene-edited intervention stands in stark contrast to the excitement surrounding the successful use of another experimental gene-edited intervention in an infant boy in Philadelphia just about a year earlier.1,2 Shrouded in secrecy, fueled by parental funding, and involving a flawed consent process, the Shanghai case casts a shadow on the budding field of personalized medicine using gene-editing. Given limited publicly available information, it would be premature to draw firm conclusions about the Shanghai case. However, enough is known to prompt reflection upon the limitations of some existing practices intended to protect patients seeking what I term here individualized interventions involving gene-editing (IIIGE) and identify potential opportunities to improve them. These include matters related to oversight, reporting patient outcomes, financial support, and consent. New IIIGE aim primarily at treating individual patients, yet presently they are often inherently experimental constructs. As such, they are sometimes termed “individualized therapeutics” or “N-of-1 studies,” but it is perhaps surprisingly difficult to strictly categorize their initial use as clinical medicine, medical research or medical innovation.3 However, how they are categorized has implications for appropriate oversight. Although regulatory approaches regarding IIIGE differ globally, there seems to be consensus that prospective oversight is critical.3 The Shanghai case raises important questions about the adequacy of local review alone based on concerns about the approved approach raised by experts.1 It also highlights the obligation to provide review bodies with emerging safety information, since this seemingly did not occur in the Shanghai case and may have altered what was done.1 Although appropriate oversight may reduce intervention-related risks of IIIGE, it can’t necessarily prevent all bad outcomes. However, there is a clear ethical responsibility to promptly report such outcomes since doing so provides scientific, clinical, and patient communities with information that can inform decision-making and perhaps prevent harm to others.4 Although the local ethics committee ostensibly was notified of the Shanghai patient’s death, no other reporting was apparently done for nearly 16 months.1 For most clinical research, there is broad agreement that patients and their families ought not to be charged for experimental products and the costs of research. In contrast, in certain health care systems, patients, families, and insurers may be responsible for some of the costs of clinical care. At times, absent other sources of support, patient funding may be the only means to develop and access a potentially therapeutic approach that lies at the intersection of research and clinical care. This was apparently so in the Shanghai case where the parents funded substantial costs for developing and preclinical testing of the intervention. Of course, it is understandable that the patient’s parents wanted the best possible care for their child. Nevertheless, there are tangible ethical concerns about patient-sponsored research including those related to undermining integrity and fairness.5,6,7,8,9,10 While this literature is arguably not yet well-developed for IIIGE, it seems reasonable to expect that when patients sponsor research, there are formal agreements regarding the amount of support and how those funds will be used. In addition, such arrangements should undergo independent review to ensure not only compliance with local laws and policies, but also that they do not pose threats to patient welfare and scientific integrity.6 Currently available information paints a very different picture of the Shanghai case, where the researchers evidently made repeated asks for additional funds and personal gifts without any mention of these arrangements having undergone an independent review.1 Finally, it is widely recognized that patients or their legally authorized representatives must provide consent to experimental interventions, most clinical research and some, especially risky, medical interventions. To be meaningful, the informed consent process ideally involves substantial information exchange over time, providing an opportunity for patients or their legally authorized representatives to understand a proposed intervention, including its risks, potential benefits, and alternatives. With such understanding, patients or their legally authorized representatives voluntarily choose whether to proceed and, in many jurisdictions, indicate their authorization on a consent document. The Shanghai case underscores the challenges associated with obtaining consent for IIIGE. On the positive side, the patient’s parents apparently engaged in many conversations with scientists and clinicians, which were recorded, providing an opportunity to revisit them and thereby promote understanding. Yet, according to those who were interviewed and reviewed the consent document, the researcher “and his team downplayed the trial’s risks in describing them to the parents” (Borrell, p. 348).1 For instance, reportedly the researcher indicated that he “could ensure there would be no safety catastrophes” (Borrell, p. 349).1 And remarkably, “nowhere did the [consent] form explicitly indicate that any of this could end in death, nor did that come up during any conversations” (Borrell, p. 352).1 If true, these are glaring problems. Another troubling aspect of consent in the Shanghai case relates to the statement in the consent document concerning cost: “Participation in this study will not incur any additional costs to you. All expenses will be borne by the sponsor, Lanqi Xintu Gene Technology” (Borrell, p. 352).1 Because the parents provided substantial financial support for developing the intervention, this statement makes consent a charade. Moreover, given that the parents were so financially and personally invested in the intervention, it is hard to imagine that the actual consent process was anything other than pro forma, leaving little room for voluntary choice. Even if disclosure had been done properly, obtaining consent for IIIGE can involve the possibility of misperceptions.7 In particular, a “therapeutic misestimation” involves overestimating a belief in the likelihood that a particular intervention will be effective and safe. In contrast, “therapeutic optimism” involves the hope that a particular intervention will be safe and effective.11 There is of course nothing wrong with therapeutic optimism and hope provided they do not translate into therapeutic misestimation, which may confound decision making. Accordingly, it is essential that communication about IIIGE be accurate. For example, following older recommendations to term early gene therapies “gene transfer experiments,”12 because IIIGE have not yet been proven to be effective and safe, using the term “intervention” rather than “therapeutic” seems denotatively and connotatively preferable. In conclusion, we must learn from the apparent failures in the Shanghai case if the goals of IIIGE are to be realized. First, guidance should be developed to ensure that independent prospective oversight of IIIGE is fit for purpose. This includes the need for rigorous scientific and competent clinical review without being unduly burdensome.13,14 In addition, procedural mechanisms should ensure that all necessary information is incorporated in the review. Second, prompt public reporting about outcomes, especially those that are unexpected or adverse, is essential to enhance decision-making for others and contribute to generalizable knowledge. Third, additional guidance should be developed regarding when and how patient support for IIIGE is appropriate. Fourth, at minimum, consent for IIIGE must meet established standards, be honest and accurate, and be sensitive to this unique context.3 Similarly, akin to experimental stem cell therapies, a professional standard for consent would be welcome.15 Consideration should also be given to having consent obtained by an otherwise uninvolved but knowledgeable clinician. Nevertheless, data are needed to help inform the implementation of meaningful consent processes for IIIGE. Measures such as these promise to promote the ethically responsible development of safe and effective IIIGE that would potentially benefit a great many individuals with rare diseases globally. Acknowledgments The Greenwall Foundation (Making a Difference Grant: “Ethical Framework for n-of-1 Clinical Trials of Genome Editor Therapeutics for Personalized, Single-Dose Therapies”). Gregory Newby, PhD, and Debra J.H. Mathews, PhD, MA, provided helpful suggestions on an earlier version of this paper. Declaration of interests Jeremy Sugarman is a consultant to Merck KGaA, Merck, Moderna, Thermo Fisher, and Fujifilm. He previously served on the Clinical Advisory Committee for Aspen Neurosciences, Inc. None of these activities is related to the material described in this report.